A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Atopic Dermatitis, Healthy Participants

In brief

This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis. Parts A and B are randomized, double-blind, placebo-controlled single and multiple ascending dose cohorts in healthy adults, that will assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of BYN-001. Part C will assess BYN-001 in adults with moderate to severe atopic dermatitis.

Key facts

Study ID

NCT07746817

Run by

Bionyra Pharma

People needed

56

Starts

2026-08-01

Expected to finish

2028-12-31

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.